Stabilizing Supersaturated X-ray Contrast Agent Solutions
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Supersaturated X-ray contrast agent solutions, such as Ioforminol, are prone to crystallization during storage due to their thermodynamic instability, which can lead to precipitation and degradation, especially when subjected to high heat loads, affecting the physical stability and safety of the diagnostic composition.
Innovation Solution
Incorporating a structurally related non-ionic iodinated dimeric compound, such as Iodixanol, as an inhibitor of primary nucleation and crystal growth to stabilize the Ioforminol composition, preventing crystallization and maintaining stability during storage.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If Ioforminol is formulated as a supersaturated solution to achieve high contrast enhancement, then diagnostic efficacy is improved, but physical stability deteriorates due to crystallization during storage
Solution Approach 1:
A structurally related non-ionic iodinated dimeric compound is introduced as an intermediary substance that interferes with the crystallization process of Ioforminol. This mediator prevents primary nucleation and crystal growth through molecular interaction, allowing the supersaturated solution to remain stable during storage while maintaining its high contrast enhancement capability
Solution Approach 2:
The solubility parameters and crystallization kinetics are modified by adding the structurally related compound. This changes the thermodynamic and kinetic parameters of the system, creating a new stable state where the supersaturated Ioforminol solution does not undergo spontaneous crystallization during storage
2Manufacturing precision
If heating is applied to ensure complete dissolution of Ioforminol, then manufacturing precision is improved, but harmful effects increase due to degradation at high temperatures
Solution Approach 1:
The structurally related non-ionic iodinated dimeric compound acts as a protective intermediary that stabilizes Ioforminol molecules during thermal processing. This mediator reduces the rate of thermal degradation by interfering with decomposition pathways, allowing effective dissolution heating while minimizing harmful degradation products
Solution Approach 2:
The stabilizing compound is incorporated into the formulation before the heating step to provide preemptive protection against thermal degradation. This prior cushioning creates a protective environment that buffers Ioforminol against the harmful effects of high-temperature processing during manufacturing
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The use of Iodixanol as an inhibitor significantly delays crystallization, ensuring the stability and safety of the Ioforminol solution, even at elevated storage temperatures, by preventing nucleation and crystal growth, thus maintaining the diagnostic quality and reducing adverse effects.
Implementation Method 1
Incorporating a structurally related non-ionic iodinated dimeric compound, such as Iodixanol, as an inhibitor of primary nucleation and crystal growth to stabilize the Ioforminol composition
Implementation Method 2
The use of Iodixanol as an inhibitor significantly delays crystallization, ensuring the stability and safety of the Ioforminol solution, even at elevated storage temperatures, by preventing nucleation and crystal growth
Data Source
AI summary
The invention relates to a composition comprising a non-ionic X-ray contrast agent in a pharmaceutically acceptable carrier, and particularly to a supersaturated X-ray composition comprising X-ray contrast agents with a high dissolution temperature in water. Particularly, the invention provides such composition which is stable, and wherein crystallisation during storage is avoided. In a preferred aspect the X-ray contrast agent is Ioforminol and the composition includes a nucleation-and growth inhibitor. The invention further relates to a process for the preparation of such stable diagnostic X-ray composition.